| Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y |
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis. |
zacks.com |
2025-05-08 17:10:55 |
Czytaj oryginał (ang.) |
| Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript |
Amarin Corporation plc (NASDAQ:AMRN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Operator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin. |
seekingalpha.com |
2025-05-07 15:01:18 |
Czytaj oryginał (ang.) |
| Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement |
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – |
globenewswire.com |
2025-04-29 20:15:00 |
Czytaj oryginał (ang.) |
| Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 |
DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. |
globenewswire.com |
2025-04-28 20:15:00 |
Czytaj oryginał (ang.) |
| Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change |
DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company's previously announced Ratio Change on its American Depositary Shares (“ADS”) -- an action in which the Company will effect a ratio change from one (1) ADS representing one (1) ordinary share to a new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). |
globenewswire.com |
2025-04-09 11:30:00 |
Czytaj oryginał (ang.) |
| Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors |
DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. |
globenewswire.com |
2025-04-07 11:30:00 |
Czytaj oryginał (ang.) |
| Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance |
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the “Concerned Shareholder Group” or “we”), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”), today issued the following open letter to the Company's Board of Directors. *** Amarin Corporation plc ATTN: Board of Directors (the “Board”) 88 Harcourt Street Dublin 2, Ireland. |
businesswire.com |
2025-03-19 14:45:00 |
Czytaj oryginał (ang.) |
| New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo |
DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 29-31, 2025, in Chicago, IL. |
globenewswire.com |
2025-03-19 09:30:00 |
Czytaj oryginał (ang.) |
| Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript |
Amarin Corporation plc (NASDAQ:AMRN ) Q4 2024 Earnings Conference Call March 12, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Operator Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2024 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin. |
seekingalpha.com |
2025-03-12 12:30:54 |
Czytaj oryginał (ang.) |
| Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering |
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled Low-Density Lipoprotein Cholesterol ( |
globenewswire.com |
2025-02-27 11:00:00 |
Czytaj oryginał (ang.) |
| Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 |
DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and full year 2024 results followed by Q&A on Wednesday, March 12th, 2025, at 8:00 a.m. ET. |
globenewswire.com |
2025-02-19 10:30:00 |
Czytaj oryginał (ang.) |
| Amarin Receives National Reimbursement for VAZKEPA® in Italy |
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients 1 -- -- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe -- |
globenewswire.com |
2024-12-16 09:00:00 |
Czytaj oryginał (ang.) |
| Amarin Appoints Peter Fishman Chief Financial Officer |
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company |
globenewswire.com |
2024-12-13 11:00:00 |
Czytaj oryginał (ang.) |
| After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN) |
Amarin (AMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-11-19 12:35:41 |
Czytaj oryginał (ang.) |
| Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates |
AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year. |
zacks.com |
2024-10-31 12:36:14 |
Czytaj oryginał (ang.) |
| Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript |
Amarin Corporation plc (NASDAQ:AMRN ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Paul Choi - Goldman Sachs Group Inc. Operator Welcome to Amarin Corporation's Conference Call to discuss its Third Quarter 2024 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin. |
seekingalpha.com |
2024-10-30 22:50:31 |
Czytaj oryginał (ang.) |
| Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting |
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Spain. |
globenewswire.com |
2024-09-09 11:30:00 |
Czytaj oryginał (ang.) |
| Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress |
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024. |
globenewswire.com |
2024-08-22 12:30:00 |
Czytaj oryginał (ang.) |
| Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat |
Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. |
zacks.com |
2024-08-01 18:00:21 |
Czytaj oryginał (ang.) |
| Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript |
Amarin Corporation plc (NASDAQ:AMRN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Aaron Berg – President and Chief Executive Officer Tom Reilly – Chief Financial Officer Jonathan Provoost – Executive Vice President, Chief Legal and Compliance Officer Steven Ketchum – Executive Vice President, President-R&D, Chief Scientific Officer Conference Call Participants Carvey Leung – Cantor Jessica Fye – JPMorgan Paul Choi – Goldman Sachs Operator Welcome to Amarin Corporation's Conference Call to discuss its Second Quarter 2024 Business Update and Financial Results. I would now like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin. |
seekingalpha.com |
2024-07-31 16:28:03 |
Czytaj oryginał (ang.) |
| Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update |
-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation – -- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. |
globenewswire.com |
2024-07-31 11:00:00 |
Czytaj oryginał (ang.) |
| 3 Breakthrough Stocks Under $10 Set for Massive Upside |
Uncovering affordable breakthrough stocks under $10 in the portfolio can lead to high-price return opportunities. Here, the focus is on three such stocks, each demonstrating strong fundamentals that signal high upside potential. |
investorplace.com |
2024-07-29 18:26:10 |
Czytaj oryginał (ang.) |
| Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal |
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe -- |
globenewswire.com |
2024-07-17 20:15:00 |
Czytaj oryginał (ang.) |
| Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 |
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. |
globenewswire.com |
2024-07-17 12:00:00 |
Czytaj oryginał (ang.) |
| Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) |
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- |
globenewswire.com |
2024-07-08 11:30:00 |
Czytaj oryginał (ang.) |
| LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok |
LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin |
globenewswire.com |
2024-06-07 23:16:00 |
Czytaj oryginał (ang.) |
| Amarin Board of Directors Announces CEO Transition |
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- |
globenewswire.com |
2024-06-04 11:30:00 |
Czytaj oryginał (ang.) |
| Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. |
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT 1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- |
globenewswire.com |
2024-05-28 12:15:00 |
Czytaj oryginał (ang.) |
| Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference |
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference. |
globenewswire.com |
2024-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? |
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year. |
zacks.com |
2024-05-03 14:46:57 |
Czytaj oryginał (ang.) |
| Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates |
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition. |
zacks.com |
2024-05-01 17:36:04 |
Czytaj oryginał (ang.) |